|
|
|
|
International Clinical Trials |
| |
| International Clinical Trials (ICT) is a specialist journal designed to provide global coverage of
key topics pertinent to the clinical trials sector.
Published quarterly, the journal offers a platform of
communication and information-sharing for executive and strategic decision makers, seeking
out new trends and marketing opportunities, as well as putting a spotlight on the latest innovations coming to market. ICT is specifically designed to be of interest to those actively seeking to source services for improved efficiency in what is an increasingly competitive market.
Prompted by the synergies between trial operations and wider contract research and outsourcing
issues, ICT joined forces with sister title European Pharmaceutical Contractor (EPC) in late-2015,
in a move that brings added value to both brands. With EPC now an inserted edition within ICT,
industry practitioners across these complementary subject areas now
have unrivalled access
to a wealth of shared views and analyses.
Connect with us on Twitter: follow @IntClinTrials
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
Veristat Launches Strategic Resourcing to Build Greater Flexibility in its Suite of Engagement Models
SOUTHBOROUGH, MA – 29 March 2022 – Veristat, a scientific-minded
global clinical research organization (CRO), announced today the
formalization of its Strategic Resourcing solution to offer clients the
delivery of clinical development and regulatory expertise options fully
tailored to their needs. Clients now have access to difficult-to-find
experts dedicated to a specific requirement or function to meet their
objectives and timelines.
More info >> |
|
 |
White Papers |
 |
|
Pandemic respiratory vaccine clinical trials: a departure from business as usual
ICON plc
Around the world, the “V” words are on everyone’s lips: Virus and Vaccines. In response to the urgent need for a vaccine for COVID-19, researchers are, at time of publication, running 500+ clinical trials (and counting) on a number of antivirals, antibodies and vaccines. Promising possibilities range from novel new drugs/vaccines, repurposing treatments currently indicated for HIV, Ebola and malaria, to monoclonal antibodies and immune serum.
More info >> |
|
|
